目的 探讨白蛋白-胆红素（ALBI）、简易白蛋白-胆红素（EZ-ALBI）及血小板-白蛋白-胆红素（PALBI）评分对HCV相关肝细胞癌（HCV-HCC）患者2年生存期的预测价值。 方法 回顾性分析2020年1月—2022年1月于昆明市第三人民医院住院治疗的174例HCV-HCC患者临床资料，随访时间为入院后2年。根据随访结果将患者分为生存组（n=95）和死亡组（n=79）。计量资料两组间比较采用成组t检验或Mann-Whitney U检验。计数资料两组间比较采用χ²检验。采用单因素和多因素Cox比例风险回归模型分析HCV-HCC患者生存的影响因素。通过Kaplan-Meier法绘制生存曲线，分析不同EZ-ALBI分级HCV-HCC患者的2年生存率，并使用Log-rank检验进行组间比较。 结果 生存组与死亡组患者比较，PLT、AST、TBil、Alb、AFP、前白蛋白、凝血酶原时间、国际标准化比值、PALBI评分、ALBI评分、EZ-ALBI评分、终末期肝病模型（MELD）评分、HCV基因分型、腹腔积液、血管侵犯差异均有统计学意义（P值均<0.05）。单因素Cox回归分析结果显示，AST、Alb、AFP、ALBI评分、EZ-ALBI评分、PALBI评分、MELD评分、巴塞罗那临床肝癌分期和腹腔积液是患者生存的影响因素（P值均<0.05）；进一步多因素Cox回归分析结果显示，EZ-ALBI评分（HR=1.850，95%CI：1.054～3.247，P=0.032）和腹腔积液（HR=1.993，95%CI：1.030～3.858，P=0.041）是HCV-HCC患者生存的独立危险因素。生存曲线分析结果显示，EZ-ALBI 1级、2级、3级患者的2年生存率分别为90.9%、60.2%和32.2%，不同EZ-ALBI分级患者累积生存率比较，差异有统计学意义（χ²=26.294，P<0.001）。 结论 EZ-ALBI评分及有无腹腔积液可作为HCV-HCC患者生存情况的预测指标。

Objective To investigate the value of albumin-bilirubin （ALBI），easy albumin-bilirubin （EZ-ALBI），and platelet-albumin-bilirubin （PALBI） scores in predicting 2-year survival in patients with HCV-associated hepatocellular carcinoma （HCV-HCC）. Methods A retrospective analysis was performed for the clinical data of 174 patients with HCV-HCC who were admitted to The Third People’s Hospital of Kunming from January 2020 to January 2022，and the patients were followed up till 2 years after admission. According to the follow-up results，the patients were divided into survival group with 95 patients and death group with 79 patients. The independent-samples t test or the Mann-Whitney U test was used for comparison of continuous data between two groups，and the chi-square test was used for comparison of categorical data between two groups. Univariate and multivariate Cox proportional-hazards regression model analyses were used to investigate the influencing factors for the survival of HCV-HCC patients. The Kaplan-Meier method was used to plot survival curves and analyze the 2-year survival rate of HCV-HCC patients with different EZ-ALBI grades，and the log-rank test was used for comparison between groups. Results There were significant differences between the survival group and the death group in platelet count，aspartate aminotransferase （AST），total bilirubin，albumin （Alb），alpha-fetoprotein （AFP），prealbumin，prothrombin time，international normalized ratio，PALBI score，ALBI score，EZ-ALBI score，Model for End-Stage Liver Disease （MELD） score，HCV genotype，peritoneal effusion，and vascular invasion （all P<0.05）. The univariate Cox regression analysis showed that AST，Alb，AFP，ALBI score，EZ-ALBI score，PALBI score，MELD score，Barcelona Clinic Liver Cancer Staging，and peritoneal effusion were influencing factors for the survival of patients （all P<0.05），and the multivariate Cox regression analysis showed that EZ-ALBI score （hazard ratio ［HR］=1.850，95% confidence interval ［CI］： 1.054 — 3.247，P=0.032） and peritoneal effusion （HR=1.993，95%CI： 1.030 — 3.858，P=0.041） were independent risk factors for the survival of HCV-HCC patients. The survival curve analysis showed that the patients with EZ-ALBI grade 1/2/3 had a 2-year survival rate of 90.9%，60.2%，and 32.2%，respectively，and there was a significant difference in cumulative survival rate between the patients with different EZ-ALBI grades （χ²=26.294，P<0.001）. Conclusion EZ-ALBI score and the presence or absence of peritoneal effusion can be used as predictors of the survival of HCV-HCC patients.